Los Angeles Capital Management
RLAY icon

Los Angeles Capital Management’s Relay Therapeutics RLAY Stock Holding History

Los Angeles Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Sell
762
-2,227
-75% -$32.3K ﹤0.01% 1877
2026
Q1 		$29.7K Sell
2,989
-44,993
-94% -$403K ﹤0.01% 1631
2025
Q4 		$352K Sell
47,982
-13,182
-22% -$94.1K ﹤0.01% 1026
2025
Q3 		$319K Sell
61,164
-7,451
-11% -$28.4K ﹤0.01% 1097
2025
Q2 		$237K Buy
68,615
+3,275
+5% +$9.74K ﹤0.01% 1129
2025
Q1 		$171K Buy
65,340
+12,570
+24% +$49.3K ﹤0.01% 1043
2024
Q4 		$217K Buy
52,770
+20,880
+65% +$114K ﹤0.01% 1035
2024
Q3 		$226K Sell
31,890
-74,279
-70% -$555K ﹤0.01% 1092
2024
Q2 		$692K Buy
106,169
+92,230
+662% +$630K ﹤0.01% 769
2024
Q1 		$116K Buy
13,939
+2,850
+26% +$27.8K ﹤0.01% 1118
2023
Q4 		$122K Hold
11,089
– – ﹤0.01% 1111
2023
Q3 		$93.3K Buy
11,089
+175
+2% +$1.88K ﹤0.01% 1093
2023
Q2 		$137K Buy
+10,914
New +$136K ﹤0.01% 1134
2022
Q4 		– Sell
-10,604
Closed -$237K – 1266
2022
Q3 		$237K Buy
+10,604
New +$233K ﹤0.01% 1143

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Los Angeles Capital Management's RLAY Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Relay Therapeutics (RLAY) stake by 75% in Q2 2026, selling an estimated $32.3K and leaving 762 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1877.

Los Angeles Capital Management first reported a position in RLAY in Q3 2022 and has held it in 14 quarters since. The position peaked at $692K in Q2 2024. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Los Angeles Capital Management held 762 shares of Relay Therapeutics worth $14.3K as of Q2 2026.
  • Los Angeles Capital Management sold 2,227 Relay Therapeutics shares in Q2 2026, an estimated $32.3K.
  • Relay Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1877 holding.
  • Los Angeles Capital Management first reported a position in Relay Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • Los Angeles Capital Management's Relay Therapeutics position peaked at $692K in Q2 2024.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.